Eli Lilly: As Monotherapy, Imlunestrant Significantly Cut Risk of Progression/Death by 38% Vs Standard Endocrine Therapy in People With Esr1 Mutations
礼来公司:作为单药治疗,Imlunestrant显著降低了携带ESR1突变患者在标准内分泌治疗下的进展/死亡风险38%
Eli Lilly: As Monotherapy, Imlunestrant Significantly Cut Risk of Progression/Death by 38% Vs Standard Endocrine Therapy in People With Esr1 Mutations
礼来公司:作为单药治疗,Imlunestrant显著降低了携带ESR1突变患者在标准内分泌治疗下的进展/死亡风险38%
使用浏览器的分享功能,分享给你的好友吧